Education

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

30 minutes to Watch

This video demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.

Please note that this is the video version of the Legendary Conversations podcast Episode Four: Let's talk gout (part 2).

Contributor
He Ako Hiringa
30 November 2021
30 minutes to Listen

This podcast demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.

Please note that this is the podcast version of the video Let's talk gout.

Contributor
He Ako Hiringa
30 November 2021
1 minute to Read

Prescribers are instrumental in framing a medicine positively or negatively, setting patient expectations. Optimising these expectations during a short consult can enhance and sustain benefits. Conversely, highlighting negative information may lead to increased experience, and reporting, of adverse events, and to poor adherence.

Contributor
He Ako Hiringa
26 November 2021
30 minutes to Listen

Episode three of our Legendary Conversations podcast is out now! Listen to three experts as they discuss attitudes towards gout and how to better communicate with patients to improve gout outcomes. 

Contributor
Professor Nicola Dalbeth, Carla White, Meihana Douglas
26 November 2021
10 minutes to Read + 2 minutes to Watch

Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.

An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box. 

Contributor
He Ako Hiringa
15 November 2021
11 minutes to Listen

Episode two of our Legendary Conversations podcast is out now! Listen to a scripted discussion that uses the Ask, Build, Check health literacy model when talking with a patient about starting a new medicine.

Contributor
He Ako Hiringa
28 October 2021

The jury is in – usual gout care isn’t working well, especially for Māori and Pacific peoples, who are disproportionately affected by this common disorder.

What potential tools are readily available to reduce gout harm? Specific clinician actions!  

Read the bulletin here.

Contributor
He Ako Hiringa
26 October 2021

Looking for up-to-date information on gout? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
18 October 2021
45 minutes to Delve

Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.

Contributor
Dr Ryan Paul
13 October 2021
17 minutes to Listen

Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know. 

Contributor
Professor Keith Petrie
11 October 2021
21 minutes to Read

Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.

30 September 2021

Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.  

As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
27 September 2021